The triglyceride-glucose index: A smarter way to measure insulin resistance

Most people who go to the doctor for a metabolic checkup leave with a fasting glucose number and, maybe, a cholesterol panel. If the glucose is below 100 mg/dL, the conversation ends: “You’re fine.” But an increasingly compelling body of research suggests that this approach misses something important — the degree to which the body has already become resistant to insulin, a process that can be silently underway for a decade before fasting glucose budges.

Enter the Triglyceride-Glucose (TyG) index — a simple, inexpensive calculation derived from two values that appear on nearly every standard blood panel. It doesn’t require a specialized lab test, an oral glucose tolerance test, or a hyperinsulinemic-euglycemic clamp (the gold standard for measuring insulin resistance but obviously impractical for routine use). All you need is your fasting triglyceride level and your fasting glucose level, and the formula does the rest.

What you’ll learn:

• What the TyG index is and how to calculate it
• The science: why TyG reflects insulin resistance biology
• TyG vs. HOMA-IR: which is better?
• TyG and cardiovascular risk: what the research shows
• Optimal vs. high-risk TyG values
• 6 strategies to improve your TyG index
• How to monitor your metabolic health over time
• How SuperAge integrates TyG into your metabolic aging profile
• Frequently asked questions

---

What Is the TyG Index and How Do You Calculate It?

The Triglyceride-Glucose index is a surrogate marker of insulin resistance — the condition in which cells become less responsive to insulin’s signal to take up glucose, forcing the pancreas to produce progressively more insulin to maintain normal blood sugar levels.

Quick definition: The TyG index is a calculated biomarker of insulin resistance derived from fasting triglycerides and fasting glucose. Higher values predict metabolic syndrome, cardiovascular disease, type 2 diabetes, and accelerated biological aging.

The formula

TyG index = Ln[Triglycerides (mg/dL) × Fasting Glucose (mg/dL) / 2]

Or equivalently:

TyG index = [Ln(TG) + Ln(FG) − Ln(2)]

Where:

• Ln = natural logarithm
• TG = fasting triglycerides in mg/dL
• FG = fasting glucose in mg/dL

Worked example

A person with:

• Fasting triglycerides: 140 mg/dL
• Fasting glucose: 95 mg/dL

TyG = Ln(140 × 95 / 2) = Ln(6,650) ≈ 8.80

This falls in the borderline-high range (see values section below).

Why this formula captures insulin resistance

The biological rationale is elegant: both fasting triglycerides and fasting glucose are direct downstream consequences of insulin resistance. When insulin signaling is impaired:

1. Glucose clearance from the blood slows, as peripheral tissues (muscle, fat) are less able to take it up in response to insulin
2. Hepatic de novo lipogenesis accelerates — the liver converts excess glucose to triglycerides, overproducing VLDL particles
3. Lipolysis in adipose tissue increases — fat cells release more free fatty acids, which drive further hepatic triglyceride synthesis

The TyG index therefore captures both glucotoxicity and lipotoxicity simultaneously, reflecting the two-hit nature of metabolic dysfunction.

---

The Science: Why TyG Reflects Insulin Resistance Biology

The insulin resistance spectrum

Insulin resistance is not a binary condition. It exists on a spectrum — from mild, subclinical impairment (detectable only with sensitive tests) to full type 2 diabetes (where the glucose elevations become unmissable). The tragedy of conventional metabolic screening is that it focuses almost exclusively on the late stage of this spectrum: fasting glucose above 100 mg/dL or HbA1c above 5.7%.

By the time fasting glucose is elevated, insulin resistance has typically been present for 5–15 years. The pancreatic beta cells have been compensating by secreting ever-larger amounts of insulin — keeping glucose “normal” while insulin levels are 2–5 times higher than optimal. This compensatory hyperinsulinemia is itself damaging: it drives visceral fat accumulation, promotes atherosclerosis, accelerates cellular aging, and increases cancer risk.

The TyG index is sensitive enough to detect insulin resistance at this earlier, compensated stage — where fasting insulin is elevated but glucose is still normal.

The triglyceride-HDL axis

The relationship between triglycerides and HDL cholesterol is an important complement to the TyG index. In insulin-resistant individuals, VLDL (triglyceride-rich lipoprotein) production is elevated, while HDL is paradoxically low — a pattern sometimes called dyslipidemia of insulin resistance. The triglycerides-to-HDL ratio is itself a validated cardiovascular risk marker and surrogate of insulin resistance, and it correlates closely with TyG.

TyG and adipose tissue dysfunction

One reason TyG is such a powerful integrative marker is that it captures adipose tissue dysfunction — the state in which fat cells become inflamed, insulin-resistant, and prone to ectopic lipid deposition. When adipose tissue dysfunction is severe:

• Free fatty acid flux from fat to liver increases
• Hepatic triglyceride synthesis accelerates
• Liver begins storing fat (hepatic steatosis — the first stage of NAFLD)
• Systemic inflammation rises (TNF-α, IL-6, CRP)

This constellation — high triglycerides, elevated glucose, low HDL, visceral adiposity, inflammation — is the metabolic syndrome phenotype, and TyG sits at its biochemical center.

---

TyG vs. HOMA-IR: Which Is Better?

HOMA-IR (Homeostatic Model Assessment of Insulin Resistance) is the most widely used surrogate marker of insulin resistance in clinical research:

HOMA-IR = [Fasting Insulin (μIU/mL) × Fasting Glucose (mg/dL)] / 405

Both TyG and HOMA-IR are validated surrogates for the hyperinsulinemic-euglycemic clamp. Their key differences:

Feature	TyG Index	HOMA-IR
Tests required	Triglycerides + Glucose	Insulin + Glucose
Cost	Low (standard panel)	Moderate (insulin add-on)
Availability	Universal	Variable (insulin not always measured)
Reflects hepatic IR	Yes (triglycerides = liver output)	Yes (via glucose/insulin ratio)
Reflects adipose IR	Yes (lipolysis drives TG)	Partially
Sensitivity for early IR	Moderate-high	Moderate

Several studies have found TyG to be superior to HOMA-IR in predicting specific outcomes:

• A 2016 study in Cardiovascular Diabetology found TyG had significantly better predictive value for subclinical atherosclerosis (measured by carotid intima-media thickness) than HOMA-IR
• A meta-analysis across diverse populations found TyG more strongly predicted incident cardiovascular events than HOMA-IR
• TyG showed better performance for predicting new-onset hypertension in normotensive adults

The primary advantage of HOMA-IR is that it directly measures insulin, making it more specific in some metabolic contexts. The advantage of TyG is its universal availability — triglycerides and glucose appear on virtually every standard blood panel, requiring no additional testing.

In practice, the two measures are complementary. If your lab panel includes fasting insulin, use both. If not, TyG is the next best option and arguably more accessible for longitudinal tracking.

---

TyG and Cardiovascular Risk: What the Research Shows

The cardiovascular literature on TyG has expanded rapidly in the past decade, and the findings are consistent and striking.

Atherosclerosis and carotid disease

A meta-analysis of over 20 studies encompassing more than 30,000 participants found that each one-unit increase in TyG index was associated with a 60% higher odds of subclinical atherosclerosis, measured by carotid intima-media thickness and coronary artery calcium scoring.

Major adverse cardiovascular events (MACE)

A large prospective study of patients undergoing coronary angiography found that TyG index predicted major adverse cardiovascular events (heart attack, stroke, cardiovascular death) over 5 years of follow-up, independent of traditional risk factors including age, sex, blood pressure, smoking, and LDL cholesterol.

Type 2 diabetes prediction

TyG is a powerful predictor of incident type 2 diabetes:

• A 10-year prospective study found TyG in the top quartile associated with a 5–8 times higher risk of developing type 2 diabetes compared to the lowest quartile
• In a meta-analysis, TyG outperformed both fasting glucose and HbA1c alone in predicting new-onset diabetes

Non-alcoholic fatty liver disease

TyG is closely correlated with hepatic steatosis. Multiple studies have validated TyG as a non-invasive surrogate for NAFLD, with performance comparable to dedicated liver steatosis scores. Given that NAFLD is present in 25–30% of adults in developed countries and is itself a cardiovascular risk factor, TyG provides a valuable window into liver health.

TyG and biological aging

Recent research has connected TyG to accelerated biological aging through multiple pathways:

• Higher TyG correlates with shorter telomeres in cross-sectional studies
• TyG is associated with higher PhenoAge and KDM Biological Age scores, independent of chronological age
• The metabolic syndrome cluster — which TyG captures — is the most potent driver of the difference between biological and chronological age in middle-aged adults

---

Optimal vs. High-Risk TyG Values

Reference ranges for TyG vary slightly across studies and populations, but the following thresholds have been validated across multiple cohorts:

TyG Index	Interpretation
< 8.2	Optimal — low insulin resistance, low metabolic risk
8.2–8.7	Borderline — moderate insulin resistance, warrants attention
8.7–9.2	Elevated — significant insulin resistance, metabolic syndrome likely
> 9.2	High risk — severe insulin resistance, high probability of metabolic syndrome or type 2 diabetes

These values assume US units (mg/dL). If your lab reports triglycerides and glucose in mmol/L, convert to mg/dL first (multiply triglycerides by 88.57, glucose by 18.0) before applying the formula.

The cardiovascular risk threshold

In the landmark cardiovascular prediction studies, TyG above 8.7–9.0 was associated with a significantly elevated risk of MACE. Bringing TyG below 8.5 should be considered a meaningful target in metabolic health optimization.

---

6 Strategies to Improve Your TyG Index

Because TyG is driven by both fasting triglycerides and fasting glucose, any intervention that improves either (or ideally both) will lower the TyG index.

1. Reduce refined carbohydrates and added sugars

Why it works: Refined carbohydrates — particularly sucrose and fructose — are the most potent dietary drivers of hepatic de novo lipogenesis (the conversion of carbohydrates to triglycerides). Fructose, whether from added sugar or high-fructose corn syrup, almost exclusively undergoes hepatic metabolism and directly raises triglycerides with a dose-response relationship.

How to do it:

• Eliminate sugar-sweetened beverages (the highest-impact, most actionable dietary change for TyG)
• Replace refined grains (white bread, white rice, pasta) with intact whole grains, legumes, and vegetables
• Limit added sugar to below 25 g/day (6 tsp) for women, 36 g/day (9 tsp) for men
• Read food labels: sugar hides under >50 names (dextrose, maltose, evaporated cane juice, etc.)

Expected results: Eliminating sugar-sweetened beverages and refined carbohydrates can lower triglycerides by 20–40% within 4–8 weeks.

2. Exercise — especially aerobic and resistance training

Why it works: Exercise improves insulin sensitivity through multiple mechanisms: GLUT4 translocation to muscle membranes (insulin-independent glucose uptake during exercise), increased muscle glycogen capacity, reduced visceral adiposity, and improved mitochondrial function. Post-exercise, skeletal muscle acts as a glucose “sink” for up to 24–48 hours, dramatically reducing postprandial glucose and insulin spikes.

How to do it:

• Aim for at least 150 minutes of moderate-intensity aerobic exercise per week (brisk walking at ≥ 3 mph / ≥ 4.8 km/h, cycling, swimming)
• Add 2–3 resistance training sessions per week — even bodyweight training significantly improves insulin sensitivity
• Post-meal walking (10 minutes within 30 minutes of eating) is a highly effective tool for blunting glucose spikes
• High-intensity interval training (HIIT) has particularly potent effects on insulin sensitivity, often exceeding steady-state cardio for equivalent time investment

Expected results: A combined aerobic + resistance training program can lower TyG by 0.3–0.8 units within 8–12 weeks.

3. Address visceral fat

Why it works: Visceral adipose tissue (VAT) is the primary driver of the insulin resistance-dyslipidemia-inflammation cycle. Unlike subcutaneous fat, VAT is metabolically active and directly connected to the portal vein — meaning the free fatty acids it releases go straight to the liver, where they fuel triglyceride synthesis. Reducing VAT is one of the fastest ways to improve TyG.

How to do it:

• Even a 5–7% reduction in body weight produces significant reductions in VAT (disproportionate to total weight loss)
• Waist circumference is a practical proxy for VAT: target below 40 in (102 cm) for men, below 35 in (88 cm) for women
• Prioritize a moderate caloric deficit (300–500 kcal/day) sustained over time rather than rapid aggressive restriction
• Reducing visceral fat also improves fasting insulin and glucose independently

4. Adopt a low-glycemic eating pattern

Why it works: Beyond total carbohydrate quantity, the glycemic impact of carbohydrates matters. High-glycemic foods cause rapid glucose spikes, driving compensatory insulin surges. Over time, this insulin rollercoaster impairs insulin receptor sensitivity and drives triglyceride synthesis.

How to do it:

• Anchor meals around non-starchy vegetables, protein, and healthy fats, using whole grains and legumes as carbohydrate sources
• Combine carbohydrates with fiber, fat, and protein to slow gastric emptying and blunt glucose response
• Consume vinegar (1–2 tbsp of apple cider vinegar before meals) — well-studied for reducing postprandial glucose by 20–30% through inhibition of amylase and gastric emptying
• Eat carbohydrates last in a meal (vegetables and protein first) — demonstrated to significantly reduce postprandial glucose in multiple randomized studies

5. Prioritize omega-3 fatty acids

Why it works: EPA and DHA omega-3 fatty acids have robust evidence for lowering triglycerides — reducing them by 15–30% in people with elevated levels, primarily by reducing hepatic VLDL secretion. They also improve insulin sensitivity through effects on cell membrane fluidity and anti-inflammatory eicosanoid production.

How to do it:

• Eat fatty fish (salmon, sardines, mackerel, herring) at least 2–3 times per week
• Each serving of fatty fish provides approximately 1–2 g of combined EPA/DHA
• For significant triglyceride lowering in already-elevated individuals, higher doses (2–4 g EPA/DHA/day) have been used therapeutically under medical supervision

6. Optimize sleep quality and quantity

Why it works: Sleep deprivation acutely impairs insulin sensitivity — a single night of 4-hour sleep reduces insulin sensitivity by approximately 25%. Chronic sleep restriction drives elevated cortisol, increased ghrelin (hunger hormone), visceral fat accumulation, and impaired glucose metabolism. Poor sleep is an underappreciated driver of worsening TyG index over time.

How to do it:

• Target 7–9 hours of sleep per night
• Maintain consistent sleep and wake times, even on weekends (circadian disruption independently impairs glucose metabolism)
• Keep the bedroom cool (65–68°F / 18–20°C) and dark — deep sleep stages are the metabolically restorative phases
• Screen for and treat sleep apnea if suspected — untreated sleep apnea is a potent driver of insulin resistance

---

How to Monitor Your Metabolic Health Over Time

Testing schedule

Situation	Frequency
TyG optimal (< 8.2)	Every 12 months
TyG borderline (8.2–8.7)	Every 6 months
TyG elevated (> 8.7)	Every 3 months until improved
After a significant dietary or exercise change	8–12 weeks for reassessment

Complementary metabolic panel

Biomarker	Target (longevity optimal)
Fasting glucose	70–90 mg/dL
Fasting insulin	< 6 μIU/mL
Triglycerides	< 100 mg/dL
HDL cholesterol	> 50 mg/dL (women), > 40 mg/dL (men)
Triglycerides/HDL ratio	< 2.0
HbA1c	< 5.4%
hsCRP	< 1.0 mg/L

---

How SuperAge Integrates TyG into Your Metabolic Aging Profile

Metabolic health is arguably the single most important determinant of biological age in middle-aged adults. SuperAge allows you to import your full blood panel and automatically computes your TyG index alongside the complete metabolic picture — triglycerides, glucose, fasting insulin, HbA1c, and more.

The app contextualizes these values not against conventional “normal” ranges but against longevity-optimized targets, showing you where you fall on the spectrum from optimal to high-risk. And because SuperAge tracks trends over time, you can see whether your dietary and exercise interventions are moving your TyG index in the right direction — typically visible within 8–12 weeks of consistent lifestyle changes.

TyG and related metabolic markers feed directly into the PhenoAge and KDM Biological Age calculations within the app, connecting your day-to-day metabolic choices to the deepest measure of how fast you are aging at a systemic level.

Download SuperAge and add the TyG index to your metabolic monitoring toolkit — because insulin resistance is the silent engine of biological aging, and you can’t fix what you can’t measure.

---

Frequently Asked Questions

Can I calculate TyG from a standard blood test?

Yes. All you need are your fasting triglycerides and fasting glucose, both in mg/dL. Apply the formula: TyG = Ln(TG × FG / 2). Most scientific calculators, smartphone calculators, and online tools have a natural log (Ln) function. Make sure both values were obtained after a 10–12 hour fast for accurate results.

My triglycerides are normal but my glucose is slightly elevated (95–99 mg/dL) — what does this mean for TyG?

High-normal fasting glucose (95–99 mg/dL) combined with any triglyceride level above 100 mg/dL will push TyG into the borderline or elevated range. This is actually one of TyG’s strengths — it detects combined metabolic risk even when neither value alone seems alarming. In this situation, I would recommend also checking fasting insulin and the triglycerides/HDL ratio for a fuller metabolic picture.

Is TyG useful if I have type 2 diabetes or take statins?

In diagnosed type 2 diabetes, fasting glucose is already known to be dysregulated, and TyG loses some of its predictive specificity. However, TyG is still useful for tracking the cardiovascular risk component of metabolic control. In people taking statins: statins have a modest glucose-raising effect (approximately 3–5 mg/dL on fasting glucose) and can slightly affect the TyG calculation; this should be factored in when interpreting trends.

How quickly can TyG improve with lifestyle changes?

Triglycerides are among the most rapidly modifiable blood biomarkers. Eliminating sugar-sweetened beverages and refined carbohydrates can lower triglycerides by 20–40% within 4–8 weeks. Fasting glucose responds more slowly to lifestyle changes, typically over 8–16 weeks. Combined, meaningful TyG improvement (0.3–0.8 units) is typically observable within 8–12 weeks of consistent dietary and exercise changes.

---

Key Takeaways

• The TyG index is a simple, cost-free calculation from standard blood panel values that detects insulin resistance earlier and more accessibly than most clinical tests
• Formula: TyG = Ln(TG × FG / 2) using values in mg/dL; optimal is below 8.2, high-risk above 8.7–9.0
• TyG predicts cardiovascular disease, metabolic syndrome, type 2 diabetes, NAFLD, and accelerated biological aging across multiple independent populations
• In several studies TyG outperforms HOMA-IR in predicting cardiovascular events and subclinical atherosclerosis
• The most effective interventions are eliminating refined carbohydrates/sugar, regular aerobic and resistance exercise, reducing visceral fat, optimizing sleep, and increasing omega-3 intake

---

Know Your TyG Index

The most powerful metabolic risk marker in your next blood panel is already there — you just need to do the math. Calculate your TyG index now. If it’s above 8.5, you have a clear target and clear tools to bring it down.

Metabolic health is not a mystery — it’s a set of modifiable numbers. The key is measuring them, understanding them, and acting on them consistently over time.

Ready to take control of your metabolic aging? Download SuperAge and start tracking TyG, fasting insulin, glucose, and your full biological age — all in one place.

---

To add fasting insulin to the lipid-glucose picture, insulin and triglycerides together explains how the paired pattern can reveal risk before glucose crosses thresholds.

References

1. Simental-Mendía, L.E. et al. — “The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects” — Metabolic Syndrome and Related Disorders, 2008. The foundational paper establishing TyG as a validated insulin resistance surrogate.
2. Er, L.K. et al. — “Triglyceride Glucose-Body Mass Index Is a Simple and Clinically Useful Surrogate Marker for Insulin Resistance in Nondiabetic Individuals” — PLOS ONE, 2016. Comparison of TyG variants and insulin resistance in clinical populations.
3. Park, B. et al. — “Triglyceride glucose index as a predictor of incident hypertension” — Journal of Human Hypertension, 2018. TyG as a predictor of cardiovascular metabolic outcomes.
4. Zhao, Q. et al. — “Triglyceride glucose index is associated with arterial stiffness and subclinical atherosclerosis” — Cardiovascular Diabetology, 2022. Evidence for TyG’s cardiovascular predictive value.
5. Kim, M.K. et al. — “The Triglyceride-Glucose Index is a More Powerful Surrogate Marker for Predicting the Prevalence and Incidence of Type 2 Diabetes Than the HOMA-IR” — Diabetes & Metabolism Journal, 2019. Head-to-head comparison of TyG vs. HOMA-IR for diabetes prediction.
6. Zhang, S. et al. — “Triglyceride-Glucose Index Is Closely Associated with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis” — Nutrients, 2021. Evidence for TyG as a liver steatosis surrogate.
7. Levine, M.E. et al. — “An epigenetic biomarker of aging for lifespan and healthspan” — Aging, 2018. PhenoAge methodology connecting metabolic markers to biological aging.

---

Last updated: 2026-03-19. This article is regularly reviewed to ensure accuracy.